Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives

Metabolic reprogramming is a hallmark of cancer progression. Metabolic activity supports tumorigenesis and tumor progression, allowing cells to uptake essential nutrients from the environment and use the nutrients to maintain viability and support proliferation. The metabolic pathways of malignant cells are altered to accom-modate increased demand for energy, reducing equivalents, and biosynthetic precursors. Activated oncogenes coordinate with altered metabolism to control cell-autonomous pathways, which can lead to tumorigenesis when abnormalities accumulate. Clinical and preclinical studies have shown that targeting metabolic features of hematologic malignancies is an appealing therapeutic approach. This review provides a comprehensive overview of the mechanisms of metabolic reprogramming in hematologic malignancies and potential therapeutic strategies to target cancer metabolism.

Automated summary

Metabolic reprogramming, a hallmark of cancer progression, supports tumorigenesis and tumor progression by allowing cells to uptake essential nutrients and altering metabolic pathways to meet increased demands for energy and biosynthetic precursors. Activated oncogenes coordinate with altered metabolism to control cell-autonomous pathways, potentially leading to tumorigenesis. Targeting metabolic features of hematologic malignancies has shown promising therapeutic potential in both clinical and preclinical studies.